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Background: Altered expression of astrocyte elevated gene-1 (AEG-1) is associated with tumorigenesis and progression.
The present study aimed to investigate the clinical and prognostic significance of AEG-1 expression in pancreatic ductal
adenocarcinoma (PDAC).
Methods: Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and Western blot analyses were
employed to assess AEG-1 expression in three pancreatic cancer cell lines and normal pancreatic duct epithelial
cells. qRT-PCR and immunohistochemical analyses were performed to detect AEG-1 expression in ten pairs of PDAC and
normal pancreas tissues. Immunohistochemistry was then used to examine AEG-1 expression in paraffin-embedded
tissues obtained from 105 patients, and its association with clinicopathological parameters including cancer classification
was examined. Kaplan-Meier analysis was performed to study the survival rates of patients.
Results: Expression of AEG-1 mRNA and protein was markedly higher in pancreatic cancer cell lines than that in
the normal pancreatic duct epithelial cells. AEG-1 expression was evidently upregulated in PDAC tissues compared to
that of the matched distant normal pancreas tissues. qRT-PCR data revealed that the tumor/non-tumor ratio of AEG-1
expression was >1.5-fold (up to 6.5-fold). Immunohistochemical data showed that AEG-1 protein was detected in
98.09% (103/105) of PDAC tissues; and they were found to be associated with tumor size (P = 0.025), advanced clinical
stage (P = 0.004), T classification (P = 0.006), N classification (P = 0.003), and M classification (P = 0.007). Furthermore,
Kaplan-Meier analysis showed that patients with high AEG-1-expressed PDAC had shorter overall survival. A multivariate
Cox regression analysis revealed that clinical stage, T classification, and AEG-1 expression were the independent
prognostic predictors for PDAC.
Conclusions: This study suggests that AEG-1 protein was highly expressed in PDAC and associated with poor
prognosis of the patients.
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Pancreatic cancer is one of the most aggressive gastro-
intestinal malignancies, accounting for the fourth most
common cause of cancer-related deaths in the United
States and the eighth in the world [1]. Pancreatic ductal
adenocarcinoma (PDAC) is the most common type of
pancreatic cancer and is frequently diagnosed at locally* Correspondence: hy9902004@126.com
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unless otherwise stated.advanced or metastatic disease, leading to an extremely
poor prognosis clinically [2]. To date, surgery is the only
curable treatment for PDAC, as it usually is resistant to
conventional chemotherapy and radiation therapy [3].
Although recent molecular analyses of precursor lesions
revealed an association between gene alterations and
carcinogenesis of PDAC, the molecular mechanisms that
regulate the aggr7essive behavior of PDAC still remain
to be clarified [4]. The actual etiology of PDAC remains
unclear, and a number of risk factors are associated with
PDAC development including family history; chronic pan-
creatitis; diabetes; obesity; and consumption of alcohol,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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http://www.biomedcentral.com/1471-2407/14/479tobacco, sugar-sweetened drinks, and red meat [5]. PDAC
development, like all other cancers, involves multiple
genetic alterations such as oncogene activation and
tumor-suppressor gene dysfunction [2]. Thus, it is of
great value to better understand the etiology, identify
valuable diagnostic and prognostic markers, and explore
novel therapeutic strategies for this deadly disease.
Astrocyte elevated gene-1 (AEG-1) was discovered as
a novel protein induced by human immunodeficiency
virus-1 or tumor necrosis factor-α in primary human fetal
astrocytes [6-8]. AEG-1 is an oncogene and is aberrantly
elevated in different human cancers such as breast cancer,
glioblastoma cell migration, esophageal squamous cell
carcinoma, prostate cancer, and hepatocellular carcinoma
[9-15]. As a downstream target of Ha-Ras, AEG-1 plays
an essential role in promoting tumorigenesis, invasion,
metastasis, and angiogenesis [16]. Molecularly, AEG-1
promotes tumor cell proliferation by suppressing forkhead
box protein O1, induces serum-independent cell growth,
suppresses apoptosis through activation of PI3K-Akt
signaling [16-20], and increases anchorage-independent
growth of non-tumorigenic astrocytes through activation
of PI3K-Akt and nuclear factor-kappa B (NF-κB) pathway
[17,21]. Overexpression of AEG-1 promotes tumorigenesis
and progression by activating ERK, Akt and p38 MAPK
pathways by phosphorylation in hepatocellular carcinoma
[9]. However, knockdown of AEG-1 expression could
inhibit prostate cancer progression [14]. AEG-1 can
regulate human malignant glioma invasion through up-
regulation of matrix metalloproteinase-9 and activation of
NF-κB signaling pathway [11,18,21,22]. These findings
suggest that AEG-1 plays a dominant role in the develop-
ment and progression of diverse cancers. In this study, the
expression of AEG-1 messenger ribonucleic acid (mRNA)
and protein in PDAC tissues were examined for associ-
ation with clinicopathological and prognostic significance.
Methods
Cell lines and culture
Pancreatic cancer cell lines were obtained from American
Type Culture Collection (Manassas, VA). AsPC-1 was ori-
ginally isolated from ascites of a patient with a Grade 2
PDAC, while Mia Paca-2 and Panc-1 were from patients
with poorly-differentiated (G3) primary PDAC, Capan-1
was isolated from a lymph node metastasis of a PDAC
patients, BxPC-3 was isolated from a patient with pan-
creas ductal carcinoma in situ. In contrast, HPDE6 was
isolated from normal epithelial tissue of pancreatic duct.
AsPC-1 cells were maintained in RPMI-1640 medium con-
taining 10% fetal bovine serum (FBS), penicillin (50 U/ml),
and streptomycin (50 U/ml). MiaPaca-2 cells were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% FBS, 2.5% horse serum (HS), penicillin
(50 U/ml), and streptomycin (50 U/ml). Panc-1 andBxPC-3 cells were maintained in DMEM containing
10% FBS, penicillin (50 U/ml), and streptomycin (50 U/ml).
Capan-1 cells were maintained in a Dulbecco’s Modified
Eagle’s Medium supplemented with 20% fetal calf serum,
penicillin (50 U/ml) and streptomycin (50 U/ml). HPDE-6
cells were routinely cultured in keratinocyte serum-free
(KSF) medium supplemented by epidermal growth factor
and bovine pituitary extract. All cell culture supplements,
FBS, and HS were obtained from Gibco BRL (Grand
Island, NY).
Tissue specimens
Fresh PDAC tissue specimens obtained from 10 patients
and the corresponding normal tissues were obtained
from the First People’s Hospital of Yuhang District and
the First Affiliated Hospital, Zhejiang University School
of Medicine between January 2011 and December 2012.
Additionally, formalin-fixed and paraffin-embedded PDAC
tissue samples were also obtained from 105 patients
between January 2010 and December 2012. All tissue
specimens were taken from patients who underwent pan-
creatic cancer surgery, and the patients did not receive
any preoperative tumor therapy. Normal pancreas tissue
adjacent to carcinoma required at least 5 cm away from
the tumor edge. Clinical and pathological classification
and staging were determined per the World Health
Organization (WHO) classification criteria [23]. Clinico-
pathological data of these 105 patients are summarized in
Table 1. Ten pairs of fresh PDAC and matched distant
non-cancerous pancreatic tissues were frozen and stored
in liquid nitrogen until use. This study was approved by the
Ethic Committee of the First People’s Hospital of Yuhang
District and the Ethic Committee of the First Affiliated
Hospital, College of Medicine, Zhejiang University, and
each patient signed an informal consent form before
enrolled into the study.
RNA isolation and quantitative reverse transcriptase
polymerase chain reaction (qRT-PCR)
Total cellular RNA was isolated from tissue samples
using a Trizol reagent (Invitrogen, Carlsbad, CA) per the
manufacturer’s instructions. These RNA samples were
then treated with RNase-free DNase, and 2 μg of RNA
sample of each patient was subjected to complementary
deoxyribonucleic acid (cDNA) synthesis using random
hexamers. PCR amplification was performed to detect
AEG-1 cDNA using AEG-1–specific primers; and the PCR
conditions included the following: initial denaturation
of samples at 95°C for 10 min, followed by 40 cycles of
denaturation at 95°C for 10 s, primer annealing at 60°C
for 60 s, followed primer extension at 72°C for 30 s,
final extension at 72°C for 5 min, and storage at 4°C.
qPCR was then employed to determine the fold of
increase of AEG-1 mRNA in each of the primary PDAC
Table 1 Association of AEG-1 expression with clinicopathological characteristics of PDAC patients
Characteristics AEG-1 expression
Low or none N (%) High N (%) Chi-square test, P-value
Gender Male 31 (29.52) 32 (30.48) 0.172
Female 15 (14.29) 27 (25.71)
Age (years) < 60 23 (21.90) 20 (19.05) 0.096
≥ 60 23 (21.90) 39 (37.15)
Localization Head of the pancreas 28 (26.67) 46 (43.81) 0.057
Body/tail of the pancreas 18 (17.14) 13 (12.38)
Tumor size ≤ 2 10 (9.52) 4 (3.81) 0.025
> 2 36 (34.29) 55 (52.38)
Clinical Stage
I 19 (18.10) 12 (11.43) 0.004
II 6 (5.71) 4 (3.81)
III 15 (14.29) 25 (23.81)
IV 6 (5.71) 18 (17.14)
T classification
T1 10 (9.52) 4 (3.81) 0.006
T2 29 (27.62) 33 (31.43)
T3 3 (2.85) 11 (10.48)
T4 4 (3.81) 11 (10.48)
N classification N0 29 (27.62) 20 (19.05) 0.003
N1 17 (16.19) 39 (37.14)
M classification No 43 (40.95) 43 (40.95) 0.007
Yes 3 (2.86) 16 (15.24)
Histological Grades
Well-differentiated 1 (0.95) 2 (1.90) 0.052
Moderately differentiated 40 (30.10) 45 (42.86)
Poorly differentiated 4 (3.81) 13 (12.38)
Histological Types
Classical ductal adenocarcinoma 43 (40.95) 48 (45.73) 0.097
Adenosquamous carcinomas 2 (1.90) 5 (4.76)
Undifferentiated carcinomas 0 (1.00) 4 (3.81)
Mixed ducal-neuroendocrine carcinoma 1 (0.95) 2 (1.90)
Alcohol drinking No 24 (22.86) 40 (38.09) 0.104
Yes 22 (20.95) 19 (18.10)
Tobacco smoking
No 28 (26.67) 28 (26.67) 0.172
Yes 18 (17.14) 31 (29.52)
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the same patient. Expression data were normalized to the
geometric mean of housekeeping gene glyceraldehyde
3-phosphate dehydrogenase (GAPDH) to control the vari-
ability of expression levels. PCR primers were designed
using the Primer Express v 2.0 software (Applied Bio-
systems, Foster city, CA). The primers for AEG-1 were
5′-CGTGATAAGGTGCTGACTGATTC-3′ and 5′-CAG
GAAATGATGCGGTTGTAAG-3′. The primers for GAP
DH were 5′-GGGAAACTGTGGCGTGAT-3′ and 5′-GA
GTGGGTGTCGCTGTTGA-3′. These primers were syn-
thesized by Sangon Ltd (Shanghai, China). Expression datawere calculated as 2-[(Ct of AEG-1) – (Ct of GAPDH)],
where Ct represents the threshold cycle for each transcript.
Protein extraction and Western blot
The proteins were transferred to nitrocellulose membranes
(Amersham Pharmacia Biosciences, Freiburg, Germany).
AEG-1 was detected by using a rabbit polyclonal anti-AEG-
1 antibody (Abcam, Heidelberg, Germany) diluted at 1:500,
and the enhanced chemiluminescence plus Western blot
detection system (Amersham Pharmacia Biosciences). After
detection, the blots were stripped, and anti-α-tubulin was
detected using a mouse monoclonal antibody (Sigma, Saint
Figure 1 Analysis of AEG-1 expression in PDAC cell lines. (A)
Western blot. (B) qRT-PCR.
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diluted 1:5,000 in both cases.
Immunohistochemistry
Immunohistochemical analysis was performed to detect
AEG-1 protein expression in 105 PDAC tissues. In brief,
paraffin-embedded tissue blocks were cut into 4-μm thick
sections and baked at 65°C for 30 min. The sections were
then deparaffinized and rehydrated for antigenic retrieval
by submerging the sections in the ethylenediaminetetra-
acetic acid buffer and microwaved for 8 min. The sections
were then incubated in 3% hydrogen peroxide in methanol
to quench the endogenous peroxidase activity, followed by
incubation with 1% bovine serum albumin to block non-
specific binding. After that, a rabbit anti-AEG-1 antibody
(1:200; Abcam) was added onto the section and incubated
overnight at 4°C. For negative controls, the first antibody
was replaced with a normal nonimmune serum.
The immunostained tissue sections were then either
reviewed and scored blindly by two independent pathol-
ogists or subjected to the mean optical density (MOD)
quantification. For semi-quantitative analysis, the score
of each tissue section was based on both the proportion
of positively stained tumor cells and the intensity of
staining. The proportion of tumor cells was scored as
follows: 0 (no positive tumor cells), 1 (<10% positive tumor
cells), 2 (10-50% positive tumor cells), and 3 (>50% positive
tumor cells). The intensity of staining was graded per
the following criteria: 0 (no staining); 1 (weak staining =
light yellow), 2 (moderate staining = yellow brown), and
3 (strong staining = brown). The staining index (SI) was
calculated as staining intensity score x proportion of
positive tumor cells. Expression of AEG-1 in normal
pancreas epithelium and malignant lesions was deter-
mined by SI, which was scored as 0, 1, 2, 3, 4, 6, and 9.
Cutoff values for AEG-1 were chosen on the basis of a
measure of heterogeneity with the log-rank test with
respect to overall survival. An optimal cutoff value was
identified as follows: SI score of ≥ 4 was used to define
tumors with high AEG-1 expression and ≤ 3 was defined
as tumors with low expression of AEG-1 protein.
For the MOD quantification, the stained sections
were evaluated at 200× magnification using the SAMBA
4000 computerized image analysis system with Immuno
4.0 quantitative program (Image Products International,
Chantilly, VA). Ten representative microscopic fields of
each tumor sample were analyzed to determine the
MOD, which represented the concentration of the stain
or proportion of positive pixels within the whole tissue.
A negative control for each staining batch was used for
background subtraction in the quantitative analysis. The
data were then statistically analyzed using Student’s t-
test to determine the differences in average MOD values
between tumor and normal tissues.Statistical analyses
All statistical analyses were performed by using the SPSS
13.0 statistical software package (SPSS, Chicago, IL, USA).
Comparisons between groups for statistical significance
were performed with a two-tailed paired Student’s t test.
The chi-square test was used to analyze association
between AEG-1 expression and clinicopathological data.
Bivariate correlations between variables were calculated
by Spearman’s correlation coefficients, and Scatter was
used to represent the relationship between two variables.
Survival curves were plotted using Kaplan-Meier method
and compared using log-rank test. Survival data were
evaluated using univariate and multivariate Cox regression
analyses. P < 0.05 was considered statistically significant.
Results
Upregulation of AEG-1 expression in PDAC cells and tissues
qRT-PCR data showed that all PDAC lines exhibited sig-
nificantly higher (up to 8.1-folds) levels of AEG-1 mRNA
compared to the normal pancreatic ductal epithelial cells,
while Western blot analysis showed that AEG-1 protein
was highly expressed in all pancreatic cancer cell lines
including AsPC-1, Mia Paca-2, and Panc-1. However, it
was weakly expressed in normal pancreatic ductal epi-
thelial cell HPDE6 (Figure 1A and B).
After that, this finding was confirmed in 10 cases of
paired primary PDAC and adjacent non-cancerous tissues.
The data showed that AEG-1 mRNA was significantly
upregulated in PDAC tissues of all ten patients, whereas
most of the ten normal tissues only had trace amounts
of detectable AEG-1 mRNA (Figure 2). The tumor/
non-tumor (T/N) ratio of AEG-1 mRNA expression
was >1.5-fold in all cases, up to about 6.5-fold induction
Figure 2 Upregulation of AEG-1 expression in PDAC tissues. (A) qRT-PCR analysis of AEG-1 expression in each of the ten PDAC tissues
(T) and distant non-cancerous tissues (N). GAPDH was used as an internal control. Columns, mean from three parallel experiments; bars, SD.
(B) Immunohistochemical analysis of AEG-1 expression in each of the ten PDAC tissues (lower panel) and distant non-cancerous tissues (upper panel).
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was also upregulated in all ten PDAC tissue samples
compared to that of their matched distant noncancerous
tissues by immunohistochemistry (Figure 2B).
Overexpression of AEG-1 protein in archived PDAC samples
Immunohistochemistry was performed to determine AEG-
1 expression in 105 paraffin-embedded, archived PDAC
tissue samples, including four histological types of
PDAC: classical ductal adenocarcinoma, adenosquamous
carcinomas, undifferentiated carcinomas, and mixed ducal-
neuroendocrine carcinoma. AEG-1 expression was detected
in 98.09% (103/105) of these PDAC samples, and was
found to be mainly localized in the cytoplasm of tumor
cells. As shown in Figure 3A, quantitative immunohis-
tochemical data revealed that the MOD valuses of AEG-1
was upregulated in all the examined histological types of
PDAC compared to their distant normal tissues.
Figure 3B shows representative immunohistochemically-
stained tumor sections of each of the four WHO stages ofPDAC. Moderate to strong cytoplasmic staining of AEG-1
protein was observed in tumor cells in these PDAC tissues.
But, weak or negative signals were observed in normal
tissues (Figure 3B). Quantitative immunohistochemical
data revealed that the MOD values of AEG-1 staining
in all PDAC tissues were higher than that in normal
tissues, and the values increased along with progression
of tumor stages I to IV (P = 0.004, Figure 3C).
To account for the inconsistency in intensity of immu-
nostained sections, we made a scatterplot of the SI staining
and the MOD staining of AEG-1.We found that the SI
staining and the MOD staining has positive correlation
(Figure 4, R = 0.972, R Sq Linear =0.945, P = 0.0001), which
showed the SI score is credible; thus, the subsequent statis-
tical analyses used the SI of AEG-1 staining data.
Increased AEG-1 expression associated with
clinicopathological data from patients with PDAC
AEG-1 expression analyzed semi-quantitatively (See the
methods section) was strongly associated with clinical
Figure 3 Immunohistochemical analysis of AEG-1 protein overexpression in archived paraffin-embedded PDAC tissue sections.
(A) Representative images of immunohistochemical analyses of AEG-1 expression in four different histological types of PDAC. (B) Representative
images of immunohistochemical analyses of AEG-1 expression in normal pancreas and PDAC tissue specimens. (C) Statistical analyses of the
average MOD of AEG-1 staining between normal pancreas and PDAC tissues specimens of different clinical stages. *P < 0.05.
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(P = 0.003), and distant metastasis (P = 0.007; Table 1).
Spearman correlation analysis showed that high level of
AEG-1 expression was strongly associated with advanced
clinical stage (R = 0.430, P = 0.000), advanced T classifi-
cation (R = 0.284, P = 0.002), lymph node involvement
(R = 0.270, P = 0.003), and distant metastasis (R = 0.251,
P = 0.005; Table 2). However, no associations were found
between AEG-1 expression and other clinical features
such as age, gender, histological variant, history of alcohol
consumption, and tobacco smoking.
AEG-1 expression associated with poor prognosis of
patients with PDAC
Spearman correlation analysis revealed that high levels
of AEG-1 expression analyzed semi-quantitatively (See the
Methods section) were associated with shorter overall
survival of patients with PDAC (P < 0.001, correlation coef-
ficient = -0.368). Moreover, Kaplan-Meier analysis showedthat patients with low AEG-1-expressed PDAC had
longer overall survival compared to those with high
AEG-1-expressed PDAC (P < 0.001 by a log-rank test;
Figure 5). The cumulative 2-year survival rate was 38.09%
(95% confidence interval: 0.565–0.913) in patients with
low AEG-1-expressed PDAC compared to only 7.84%
(95% confidence interval: 0.403–0.697) in high AEG-1-
expressed PDAC. In addition, the multivariate Cox regres-
sion analysis showed that clinical stage, T classification,
and AEG-1 expression were independent prognostic
predictors for PDAC (Table 3).Discussion
The results obtained in this study showed that expres-
sion of AEG-1 mRNA and protein was upregulated in
PDAC cell lines and tissues. The results also showed that
elevated expression of AEG-1 protein was associated
with tumor size, clinical stage, T classification, lymph
Figure 4 Scatterplot of the SI staining and the MOD staining of AEG-1. The SI staining and the MOD staining of AEG-1 expression correlations
between variables were calculated by Spearman’s correlation coefficients. *P < 0.05.
Huang et al. BMC Cancer 2014, 14:479 Page 7 of 10
http://www.biomedcentral.com/1471-2407/14/479node, and distant metastases of PDAC. Expression of AEG-
1 protein also associated with poor prognosis and reduced
survival of patients with PDAC. Moreover, the multivariate
Cox regression analysis showed that clinical stage, T classifi-
cation, and AEG-1 expression were independent prognostic
predictors for PDAC. Further studies would verify the
results of the present study before AEG-1 could be used
as a biomarker for prediction of PDAC prognosis. Such
studies would also investigate the role and function of
AEG-1 in PDAC.
AEG-1 is an Ha-Ras–regulated gene, which plays an
essential role in promotion of tumorigenesis and cancer
invasion, metastasis, and angiogenesis [16]. A number
of studies have confirmed the potential role of AEG-1
in the development and progression of human cancers





Clinical staging 0.430 0.000
T classification 0.284 0.002
N classification 0.270 0.003
M classification 0.251 0.005whether AEG-1 expression is in parallel with the course
of carcinogenesis and cancer progression or AEG-1 is
the driver for tumor development and progression. In
either way, AEG-1 could be used as an indicator of can-
cer progression, but a mechanistic study would define
the role of AEG-1 in PDAC.
In the current study, expression of AEG-1 mRNA and
protein was upregulated in PDAC cell lines as well as
PDAC tissues. After that, AEG-1 expression was detected
in PDAC tissue specimens of 105 patients. 103 out of 105
(98.09%) specimens of PDAC tissues had moderate to
strong cytoplasmic staining of AEG-1 protein, whereas
there was no significant staining of AEG-1 detected in
the distant noncancerous pancreatic epithelial cells.
This supported the role of AEG-1 in the development
and progression of PDAC. Moreover, it is particularly
noteworthy per the study results that AEG-1 has been
found to be only localized in the cytoplasm of cancer
cells. This observation coincides with the most previous
reports that overexpression of AEG-1 could result in
the localization of the protein in the cytoplasm [28].
However, Emad et al [18,21] found that the cytoplasm
and nuclear staining of AEG-1 associated with tumor
progression, metastasis and neurodegeneration. In breast
cancer, nuclear staining of AEG-1 tends to become more
common in lesions from patients with more advanced
Figure 5 Kaplan-Meier curves of AEG-1 expression against overall survival of PDAC patients. The data were analyzed using a log-rank test
between patients with low AEG-1 expressed PDAC (full line) versus high AEG-1-expressed PDAC (dotted line). The cumulative 2-year survival rate
was 38.09% in patients with low AEG-1-expressed PDAC (n = 46) compared to only 7.84% in patients with high AEG-1-expressed PDAC (n = 59).
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http://www.biomedcentral.com/1471-2407/14/479disease stages [12]. The authors found that occasional
nuclear staining of AEG-1 was detected in clinical stage
II samples, while stage III sections displayed noticeably
increased AEG-1 nuclear localization. A large proportion
of caner cells in liver metastases revealed AEG-1Table 3 Univariate and multivariate analyses of various progn
Univariate analysis
















High expression 59translocation to the nucleus [12]. Emad [21] suggested
that AEG-1 might interact with the NF-κB complex and
correspond with the nuclear translocation of p65, but
suspected that AEG-1 activation of NF-κB was possible by
degradation of IκBα. In addition, it was recently reportedostic parameters in patients with PDAC
Multivariate analysis
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constitutive activity of NF-κB in parallel with depletion in
NF-κB-regulated genes [29]. Therefore, the present study
data further support the latter possibility. However, further
studies are needed to verify the role of AEG-1 at different
cellular localizations in the development and signal trans-
duction of PDAC.
Further analysis in the study showed a significant associ-
ation of AEG-1 expression with advanced clinical staging,
and T, N, and M classification. This suggested that AEG-1
might be useful as a biomarker to identify subsets of
patients with PDAC who had more aggressive disease.
Patients with high AEG-1-expressed PDAC had only a
7.84% cumulative 2-year survival rate, which was signifi-
cantly lower than that in patients with low AEG-1–
expressed PDAC (38.09%). The multivariate Cox regression
analysis showed that clinical stage, T classification, and
AEG-1 expression were independent prognostic predictors
for PDAC.
The ex vivo analysis of AEG-1 expression could be a
limitation of this study. An in vitro mechanistic study of
AEG-1 knockout or transgenic animal models in PDAC
cell would be important for further understanding of the
functional significance of AEG-1 in PDAC development
and progression.
Conclusions
Our current study demonstrated that up-regulation of
AEG-1 expression was associated with worse survival of
PDAC patients by showing that AEG-1 protein level is
an independent prognostic predictor for PDAC patients.
Thus, further study will confirm our current data before
used in clinical practice.
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